Bisphosphonates and mortality: confounding in observational studies?

被引:25
作者
Bergman, J. [1 ]
Nordstrom, A. [2 ,3 ]
Hommel, A. [4 ]
Kivipelto, M. [5 ,6 ,7 ]
Nordstrom, P. [1 ]
机构
[1] Umea Univ, Dept Community Med & Rehabil, Unit Geriatr Med, S-90187 Umea, Sweden
[2] Umea Univ, Sect Sustainable Hlth, Dept Publ Hlth & Clin Med, S-90187 Umea, Sweden
[3] UiT Arctic Univ Norway, Sch Sport Sci, Postboks 1621, N-9509 Alta, Norway
[4] Malmo Univ, Dept Care Sci, S-20506 Malmo, Sweden
[5] Karolinska Inst, Dept Neurobiol Sci & Soc, Div Clin Geriatr, Plan 7, S-14183 Huddinge, Sweden
[6] Karolinska Univ Hosp, Theme Aging, S-14186 Stockholm, Sweden
[7] Stockholm Sjukhem, Res & Dev Unit, Mariebergsgatan 22, S-11219 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Bisphosphonates; Death; Mortality; Observational study; Osteoporosis; HIP FRACTURE PATIENTS; ZOLEDRONIC ACID; ORAL BISPHOSPHONATES; VERTEBRAL FRACTURES; RANDOMIZED-TRIAL; CLINICAL-TRIALS; WOMEN; RISK; OSTEOPOROSIS; SURVIVAL;
D O I
10.1007/s00198-019-05097-1
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
The Summary Numerous observational studies suggest that bisphosphonates reduce mortality. This study showed that bisphosphonate use is associated with lower mortality within days of treatment, although the association was not significant until the second week. Such an early association is consistent with confounding, although an early treatment effect cannot be ruled out.IntroductionThe purpose of this study was to examine whether confounding explains why numerous observational studies show that bisphosphonate use is associated with lower mortality. To this end, we examined how soon after treatment initiation a lower mortality rate can be observed. We hypothesized that, due to confounding, the association would be observed immediately.MethodsThis was a retrospective cohort study of hip fracture patients discharged from Swedish hospitals between 1 July 2006 and 31 December 2015. The data covered 260,574 hip fracture patients and were obtained from the Swedish Hip Fracture Register and national registers. Of the 260,574 patients, 49,765 met all eligibility criteria and 10,178 were pair matched (bisphosphonate users to controls) using time-dependent propensity scores. The matching variables were age, sex, diagnoses, prescription medications, type of hip fracture, type of surgical procedure, known or suspected dementia, and physical functioning status.ResultsOver a median follow-up of 2.8 years, 2922 of the 10,178 matched patients died. The mortality rate was 7.9 deaths per 100 person-years in bisphosphonate users and 9.4 deaths in controls, which corresponded to a 15% lower mortality rate in bisphosphonate users (hazard ratio 0.85, 95% confidence interval 0.79-0.91). The risk of death was lower in bisphosphonate users from day 6 of treatment, although the association was not significant until the second week.ConclusionBisphosphonate use was associated with lower mortality within days of treatment initiation. This finding is consistent with confounding, although an early treatment effect cannot be ruled out.
引用
收藏
页码:1973 / 1982
页数:10
相关论文
共 44 条
[11]
Osteoporosis Medication and Reduced Mortality Risk in Elderly Women and Men [J].
Center, Jacqueline R. ;
Bliuc, Dana ;
Nguyen, Nguyen D. ;
Nguyen, Tuan V. ;
Eisman, John A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) :1006-1014
[12]
Potential Mediators of the Mortality Reduction With Zoledronic Acid After Hip Fracture [J].
Colon-Emeric, Cathleen S. ;
Mesenbrink, Peter ;
Lyles, Kenneth W. ;
Pieper, Carl F. ;
Boonen, Steven ;
Delmas, Pierre ;
Eriksen, Erik F. ;
Magaziner, Jay .
JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (01) :91-97
[13]
Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].
Concato, J ;
Shah, N ;
Horwitz, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892
[14]
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].
Cummings, SR ;
Black, DM ;
Thompson, DE ;
Applegate, WB ;
Barrett-Connor, E ;
Musliner, TA ;
Palermo, L ;
Prineas, R ;
Rubin, SM ;
Scott, JC ;
Vogt, T ;
Wallace, R ;
Yates, AJ ;
LaCroix, AZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082
[15]
Non-parametric assessment of non-inferiority with censored data [J].
Freitag, G ;
Lange, S ;
Munk, A .
STATISTICS IN MEDICINE, 2006, 25 (07) :1201-1217
[16]
Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study [J].
Gayat, Etienne ;
Resche-Rigon, Matthieu ;
Mary, Jean-Yves ;
Porcher, Raphael .
PHARMACEUTICAL STATISTICS, 2012, 11 (03) :222-229
[17]
Association between bisphosphonate therapy and outcomes from rehabilitation in older people [J].
Goodbrand, James A. ;
Hughes, Lloyd D. ;
Cochrane, Lynda ;
Donnan, Peter T. ;
McGilchrist, Mark ;
Frost, Helen ;
McMurdo, Marion E. T. ;
Witham, Miles D. .
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2017, 70 :195-200
[18]
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial [J].
Harris, ST ;
Watts, NB ;
Genant, HK ;
McKeever, CD ;
Hangartner, T ;
Keller, M ;
Chesnut, CH ;
Brown, J ;
Eriksen, EF ;
Hoseyni, MS ;
Axelrod, DW ;
Miller, PD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14) :1344-1352
[19]
Bisphosphonate Therapy, Death, and Cardiovascular Events Among Female Patients With CKD: A Retrospective Cohort Study [J].
Hartle, James E. ;
Tang, Xiaoqin ;
Kirchner, H. Lester ;
Bucaloiu, Ion D. ;
Sartorius, Jennifer A. ;
Pogrebnaya, Zhanna V. ;
Akers, Gwendolyn A. ;
Carnero, Guillermo E. ;
Perkins, Robert M. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 59 (05) :636-644
[20]
DEVELOPING IMPROVED OBSERVATIONAL METHODS FOR EVALUATING THERAPEUTIC EFFECTIVENESS [J].
HORWITZ, RI ;
VISCOLI, CM ;
CLEMENS, JD ;
SADOCK, RT .
AMERICAN JOURNAL OF MEDICINE, 1990, 89 (05) :630-638